Treatment of Renal Fibrosis—Turning Challenges into Opportunities

Advances in Chronic Kidney Disease

Volumn 24, Issue 2, 2017, Pages 117-129

  Klinkhammer, Barbara M ^a   Goldschmeding, Roel ^a   Floege, Jürgen ^a   Boor, Peter ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Antifibrotic therapy; Biomarker; Chronic kidney disease; Growth factors; Kidney imaging

Indexed keywords

ANTIFIBROTIC AGENT; BIOLOGICAL MARKER; DOXYCYCLINE; FRESOLIMUMAB; GCS 100; LY 2382770; PAMREVLUMAB; PIRFENIDONE; PLACEBO; STX 100; TELMISARTAN; UNCLASSIFIED DRUG; CONNECTIVE TISSUE GROWTH FACTOR; GALECTIN 3; GCS-100; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; POLYSACCHARIDE; PYRIDONE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA;

DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FIBROSIS; NONHUMAN; PATIENT SELECTION; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHOTODERMATOSIS; REVIEW; RHINOPHARYNGITIS; SEDATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; URTICARIA; ANTAGONISTS AND INHIBITORS; BIOASSAY; CHRONIC KIDNEY FAILURE; DIAGNOSTIC IMAGING; ELASTOGRAPHY; EXTRACELLULAR MATRIX; FIBROSIS; IMMUNOLOGY; KIDNEY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BIOMARKERS; CONNECTIVE TISSUE GROWTH FACTOR; ELASTICITY IMAGING TECHNIQUES; ENDPOINT DETERMINATION; EXTRACELLULAR MATRIX; FIBROSIS; GALECTIN 3; HUMANS; KIDNEY; MAGNETIC RESONANCE IMAGING; POLYSACCHARIDES; PYRIDONES; RENAL INSUFFICIENCY, CHRONIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 85014812273     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2016.11.002     Document Type: Review

References (52)

1. 1 Levey, A.S., Coresh, J., Chronic kidney disease. Lancet 379:9811 (2012), 165–180.
2. 2 Stanifer, J.W., Muiru, A., Jafar, T.H., Patel, U.D., Chronic kidney disease in low- and middle-income countries. Nephrol Dial Transplant 31:6 (2016), 868–874.
3. 3 Jha, V., Garcia-Garcia, G., Iseki, K., et al. Chronic kidney disease: global dimension and perspectives. Lancet 382:9888 (2013), 260–272.
4. 4 GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:9633 (2015), 117–171.
5. 5 Bechtel, W., McGoohan, S., Zeisberg, E.M., et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 16:5 (2010), 544–550.
6. 6 Maarouf, O.H., Aravamudhan, A., Rangarajan, D., et al. Paracrine Wnt1 drives interstitial fibrosis without inflammation by tubulointerstitial cross-talk. J Am Soc Nephrol 27:3 (2016), 781–790.
7. 7 Boor, P., Ostendorf, T., Floege, J., Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 6:11 (2010), 643–656.
8. 8 Boor, P., Floege, J., Renal allograft fibrosis: biology and therapeutic targets. Am J Transpl 15:4 (2015), 863–886.
9. 9 Tampe, D., Zeisberg, M., Potential approaches to reverse or repair renal fibrosis. Nat Rev Nephrol 10:4 (2014), 226–237.
10. 10 Fleig, S.V., Humphreys, B.D., Rationale of mesenchymal stem cell therapy in kidney injury. Nephron Clin Pract 127:1-4 (2014), 75–80.
11. 11 Hickson, L.J., Eirin, A., Lerman, L.O., Challenges and opportunities for stem cell therapy in patients with chronic kidney disease. Kidney Int 89:4 (2016), 767–778.
12. 12 Kunter, U., Rong, S., Boor, P., et al. Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol 18:6 (2007), 1754–1764.
13. 13 Klinkhammer, B.M., Kramann, R., Mallau, M., et al. Mesenchymal stem cells from rats with chronic kidney disease exhibit premature senescence and loss of regenerative potential. PLoS One, 9(3), 2014, e92115.
14. 14 Border, W.A., Noble, N.A., Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:19 (1994), 1286–1292.
15. 15 Meng, X.M., Tang, P.M., Li, J., Lan, HY., TGF-beta/Smad signaling in renal fibrosis. Front Physiol, 6, 2015, 82.
16. 16 Trachtman, H., Fervenza, F.C., Gipson, D.S., et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79:11 (2011), 1236–1243.
17. 17 Tumlin JA, Vincenti F, Fervenza FC, et al. (eds). A Phase 2, Double-Blind, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis. ASN Kidney Week; 2015; San Diego, CA. J Am Soc Nephrol. 2015.
18. 18 Cho, M.E., Kopp, J.B., Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Investig Drugs 19:2 (2010), 275–283.
19. 19 Cho, M.E., Smith, D.C., Branton, M.H., Penzak, S.R, Kopp, J.B., Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2:5 (2007), 906–913.
20. 20 Sharma, K., Ix, J.H., Mathew, A.V., et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22:6 (2011), 1144–1151.
21. 21 Kok, H.M., Falke, L.L., Goldschmeding, R., Nguyen, T.Q., Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease. Nat Rev Nephrol 10:12 (2014), 700–711.
22. 22 Adler, S.G., Schwartz, S., Williams, M.E., et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 5:8 (2010), 1420–1428.
23. 23 Henderson, N.C., Arnold, T.D., Katamura, Y., et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 19:12 (2013), 1617–1624.
24. 24 Winyard, P.J., Bao, Q., Hughes, R.C., Woolf, A.S., Epithelial galectin-3 during human nephrogenesis and childhood cystic diseases. J Am Soc Nephrol 8:11 (1997), 1647–1657.
25. 25 Drechsler, C., Delgado, G., Wanner, C., et al. Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies. J Am Soc Nephrol 26:9 (2015), 2213–2221.
26. 26 Desmedt, V., Desmedt, S., Delanghe, J.R., Speeckaert, R., Speeckaert, M.M., Galectin-3 in renal pathology: more than just an innocent bystander. Am J Nephrol 43:5 (2016), 305–317.
27. 27 Henderson, N.C., Mackinnon, A.C., Farnworth, S.L., et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172:2 (2008), 288–298.
28. 28 Okamura, D.M., Pasichnyk, K., Lopez-Guisa, J.M., et al. Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Ren Physiol 300:1 (2011), F245–F253.
29. 29 Boor, P., Sebekova, K., Ostendorf, T., Floege, J., Treatment targets in renal fibrosis. Nephrol Dial Transplant 22:12 (2007), 3391–3407.
30. 30 Buhl, E.M., Djudjaj, S., Babickova, J., et al. The role of PDGF-D in healthy and fibrotic kidneys. Kidney Int 89:4 (2016), 848–861.
31. 31 Pullen, N., Fornoni, A., Drug discovery in focal and segmental glomerulosclerosis. Kidney Int 89:6 (2016), 1211–1220.
32. 32 Friedman, S.L., Sheppard, D., Duffield, J.S., Violette, S., Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med, 5(167), 2013, 167sr.
33. 33 Zhuang, S., Liu, N., EGFR signaling in renal fibrosis. Kidney Int Suppl 4:1 (2014), 70–74.
34. 34 Sridhar, S.S., Seymour, L., Shepherd, F.A., Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4:7 (2003), 397–406.
35. 35 Fakih, M., Vincent, M., Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol 17 Suppl 1 (2010), S18–S30.
36. 36 Poosti, F., Bansal, R., Yazdani, S., et al. Selective delivery of IFN-gamma to renal interstitial myofibroblasts: a novel strategy for the treatment of renal fibrosis. FASEB J 29:3 (2015), 1029–1042.
37. 37 Prakash, J., de Borst, M.H., Lacombe, M., et al. Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. J Am Soc Nephrol 19:11 (2008), 2086–2097.
38. 38 Prakash, J., de Borst, M.H., van Loenen-Weemaes, A.M., et al. Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis. Pharm Res 25:10 (2008), 2427–2439.
39. 39 Dolman, M.E., Harmsen, S., Pieters, E.H., et al. Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. Int J Nanomedicine 7 (2012), 417–433.
40. 40 Rauen, T., Eitner, F., Fitzner, C., et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373:23 (2015), 2225–2236.
41. 41 Bohle, A., Mackensen-Haen, S., von Gise, H., Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: a morphometric contribution. Am J Nephrol 7:6 (1987), 421–433.
42. 42 Nankivell, B.J., Kuypers, D.R., Diagnosis and prevention of chronic kidney allograft loss. Lancet 378:9800 (2011), 1428–1437.
43. 43 Buchmann, T.N., Wolff, T., Bachmann, A., et al. Repeat true surveillance biopsies in kidney transplantation. Transplantation 93:9 (2012), 908–913.
44. 44 Wong, M.G., Pollock, C.A., Biomarkers in kidney fibrosis: are they useful?. Kidney Int Suppl 4:1 (2014), 79–83.
45. 45 Zeisberg, M., Zeisberg, E.M., Precision renal medicine: a roadmap towards targeted kidney fibrosis therapies. Fibrogenesis Tissue Repair, 8, 2015, 16.
46. 46 Genovese, F., Manresa, A.A., Leeming, D.J., Karsdal, M.A., Boor, P., The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?. Fibrogenesis Tissue Repair, 7(1), 2014, 4.
47. 47 Genovese, F., Boor, P., Papasotiriou, M., Leeming, D.J., Karsdal, M.A., Floege, J., Turnover of type III collagen reflects disease severity and is associated with progression and microinflammation in patients with IgA nephropathy. Nephrol Dial Transplant 31:3 (2016), 472–479.
48. 48 Ghoul, B.E., Squalli, T., Servais, A., et al. Urinary procollagen III aminoterminal propeptide (PIIINP): a fibrotest for the nephrologist. Clin J Am Soc Nephrol 5:2 (2010), 205–210.
49. 49 Togao, O., Doi, S., Kuro-o, M., Masaki, T., Yorioka, N., Takahashi, M., Assessment of renal fibrosis with diffusion-weighted MR imaging: study with murine model of unilateral ureteral obstruction. Radiology 255:3 (2010), 772–780.
50. 50 Boor, P., Perkuhn, M., Weibrecht, M., et al. Diffusion-weighted MRI does not reflect kidney fibrosis in a rat model of fibrosis. J Magn Reson Imaging 42:4 (2015), 990–998.
51. 51 Sharma, S.G., Bomback, A.S., Radhakrishnan, J., et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol 8:10 (2013), 1718–1724.
52. 52 Linde, P.G., Archdeacon, P., Breyer, M.D., et al. Overcoming barriers in kidney health-forging a platform for innovation. J Am Soc Nephrol 27:7 (2016), 1902–1910.